Takeda Canada, a subsidiary of Takeda Pharmaceutical Co. Ltd. (TAK), Thursday announced that it has finalized a Letter of Intent with pan-Canadian Pharmaceutical Alliance or pCPA for Livtencity, which is used to treat patients suffering from post-transplant cytomegalovirus infection.
The biotechnology company added that the beta herpes virus infection commonly affects transplant patients and sometimes lead to loss of transplanted organ or even death.
Following the agreement, the procedures regarding individual listing of Livtencity will be initiated, depending on the respective province or territory.
Currently, Takeda's stock is moving down 0.62 percent, to $13.31 on the New York Stock Exchange.
For comments and feedback contact: editorial@rttnews.com
Health News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.